Current treatment of chronic HBV infection: An Asian-Pacific perspective

被引：1
作者：
Liaw Y.-F. [1 ]
Chien R.-N. [1 ]
机构：
[1] Chang Gung Memorial Hospital and University, Taipei
来源：
Current Hepatitis Reports | 2009年 / 8卷 / 4期
关键词：
Chronic Hepatitis; Entecavir; HBeAg Seroconversion; Adefovir Dipivoxil; HBeAg Seroconversion Rate;
D O I：
10.1007/s11901-009-0022-x
中图分类号：
学科分类号：
摘要：
Chronic hepatitis B virus (HBV) infection is a major global health problem with potential adverse sequelae including liver cirrhosis and hepatocellular carcinoma. Of more than 350 million chronic HBV carriers, 75% reside in the Asian-Pacific region, where most countries have low-income economies. Better understanding of the natural history and immunopathogenesis of chronic HBV infection and the invention of powerful antiviral agents have improved the therapeutic strategy. Guidelines issued by major liver associations are basically similar. However, each country in the Asian-Pacific region has specific problems. Because cost is a main concern, drugs with low genetic barrier to resistance are still widely used in these countries. Modifications needed to accommodate specific situations and problems include more stringent indications for drug therapy, starting therapy with the least expensive drug, and defining stopping rules even for hepatitis B e antigen-negative patients. © 2009 Springer Science+Business Media, LLC.
引用
收藏
页码：154 / 160
页数：6
相关论文
共 55 条
  • [1] Liaw Y.F., Chu C.M., Hepatitis B virus infection, Lancet, 373, pp. 582-592, (2009)
  • [2] Fattovich G., Bortolotti F., Donato F., Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors, J Hepatol, 48, pp. 335-352, (2008)
  • [3] Liaw Y.F., Natural history of chronic hepatitis B virus infection and long-term outcome under treatment, Liver Int, 29, SUPPL. 1, pp. 100-107, (2009)
  • [4] Zoulim F., Perrillo R., Hepatitis B: Reflection on the current approach to antiviral therapy, J Hepatol, 48, (2008)
  • [5] Lok A.S.F., McMahon B.J., Chronic hepatitis B, Hepatology, 45, 2, pp. 507-539, (2007)
  • [6] Liaw Y.F., Leung N., Kao J.H., Et al., Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update, Hepatol Int, 2, pp. 263-283, (2008)
  • [7] EASL clinical practice guidelines: Management of chronic hepatitis B, J Hepatol, 50, pp. 227-242, (2009)
  • [8] Chang T.-T., Zhuang H., Jia J., Leung N.W.-Y., Guan R., Jafri S.M.W., Lesmana L.A., Liaw Y.-F., Locarnini S., Omata M., Sollano J.D., Suh D.J., Mahachai V., Phiet P.H., Sarin S.K., Yao G., Yoon S.K., Chronic hepatitis B: Treatment alert, Liver International, 26, SUPPL. 2, pp. 47-58, (2006)
  • [9] Keeffe E.B., Dieterich D.T., Han S.H., Et al., A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update, Clin Gastroenterol Hepatol, 6, pp. 1315-1341, (2008)
  • [10] Liaw Y.F., Antiviral therapies of chronic hepatitis B: Opportunities and challenges in Asia, J Hepatol, 51, pp. 403-410, (2009)
123456